Anoro Ellipta (Umeclidinium/Vilanterol) for COPD

Overview
Anoro Ellipta is a prescription drug approved by the Food and Drug Administration (FDA) as long-term, once-daily maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Anoro Ellipta is a combination drug composed of Umeclidinium and Vilanterol.

Umeclidinium is a long-acting anticholinergic drug. Vilanterol is an ultra-long-acting beta2 adrenoreceptor agonist (ultra-LABA). Both drugs are believed to work by relaxing smooth muscles in the airways.

How do I take it?
Anoro Ellipta is taken once daily by oral inhalation.

Anoro Ellipta comes in the form of foil blister pack containing powder. Anoro Ellipta is taken using the special Ellipta inhaler.

Side effects
The FDA-approved label for Anoro Ellipta lists common side effects including cold symptoms, lower respiratory infections, chest pain, neck pain, pain in extremities, muscle spasms, constipation, and diarrhea.

Rare but serious side effects listed for Anoro Ellipta include worsening glaucoma and urinary retention, paradoxical bronchospasm (bronchospasm caused by taking medication), and increased risk for asthma-related death.

For more details about this treatment, visit:

Anoro Ellipta – GSK
http://www.anoro.com/